Home | Business News | Browse by Publication | P | Pharma Marketletter

Strong data for AstraZeneca's Nexium vs NSAIDs/COX2s.

Publication: Pharma Marketletter
Publication Date: 27-MAR-06
Format: Online
Delivery: Immediate Online Access

Article Excerpt
Anglo-Swedish drug major AstraZeneca says that its antiulcer agent Nexium (esomeprazole magnesium) can reduce the incidence of gastric ulcers in patients at risk of developing them and who regularly take either non-selective non-steroidal anti-inflammatory drugs or COX-2-selective NSAIDs, according to results from two clinical trials, to be published in...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
Canada: branded drugs slip, generics grow., March 27, 2006
Japan's generic growth attracts foreign firms., March 27, 2006
Increased mortality in Aricept VaD trial cohort., March 27, 2006
GSK/S-P's Levitra 83% "effective" in patients on hypertension drugs., March 27, 2006

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.